COR Stock Recent News
COR LATEST HEADLINES
In the present market turbulence, investors may want to consider discounted stocks, such as FMS, PAHC and COR.
Fear and uncertainty have dominated the markets in 2025, with U.S. equities entering a significant correction. What began as a cautious retreat in February, sparked by policy concerns and underwhelming performance from former market leaders and Magnificent Seven stocks, like Tesla and Alphabet, has now escalated into broader selling pressure.
Cencora hit an all-time high on Friday. The post Sellers Rule The Roost Amid Tariff Wars, But This Stock Hits A High appeared first on Investor's Business Daily.
Healthcare stocks like GLID, COR, FMS and LMAT are a safe bet during times of market volatility.
Here is how Cencora (COR) and Intensity Therapeutics Inc. (INTS) have performed compared to their sector so far this year.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2025 on Wednesday, May 7, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on May 7, 2025. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Fin.
The Zacks Medical - Services industry is undergoing a transformation on massive artificial intelligence adoption. COR, DOCS and MD are set to gain the most.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.